201,087 Shares in Kenvue Inc. $KVUE Acquired by Greenland Capital Management LP

Greenland Capital Management LP bought a new stake in Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, Holdings Channel.com reports. The fund bought 201,087 shares of the company’s stock, valued at approximately $3,843,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Kenvue by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 410,874 shares of the company’s stock valued at $7,088,000 after buying an additional 84,219 shares during the period. Calamos Advisors LLC grew its stake in shares of Kenvue by 24.1% in the first quarter. Calamos Advisors LLC now owns 3,351,000 shares of the company’s stock worth $57,771,000 after acquiring an additional 651,000 shares in the last quarter. State of Wyoming increased its position in shares of Kenvue by 233.5% during the fourth quarter. State of Wyoming now owns 97,992 shares of the company’s stock worth $1,690,000 after acquiring an additional 68,609 shares during the period. Nomura Asset Management Co. Ltd. increased its position in shares of Kenvue by 21.5% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 3,491,548 shares of the company’s stock worth $60,229,000 after acquiring an additional 618,720 shares during the period. Finally, Cullen Frost Bankers Inc. raised its stake in shares of Kenvue by 19.9% in the fourth quarter. Cullen Frost Bankers Inc. now owns 431,394 shares of the company’s stock valued at $7,442,000 after acquiring an additional 71,591 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.2%

NYSE:KVUE opened at $18.82 on Wednesday. The company has a market capitalization of $36.15 billion, a PE ratio of 21.63, a P/E/G ratio of 1.37 and a beta of 0.47. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $21.84. The stock’s 50 day moving average price is $19.00 and its 200 day moving average price is $18.16. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. Kenvue’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.29 EPS. On average, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be given a $0.21 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 annualized dividend and a yield of 4.5%. Kenvue’s payout ratio is currently 96.55%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Barclays lifted their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. UBS Group decreased their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.